Form 4: Agios Pharmaceuticals Director Cynthia Smith Reports Stock Transactions

Director Cynthia Smith reports the vesting of restricted stock units and subsequent disposal of shares on June 13, 2024.

Summary

• Cynthia Smith, a director of Agios Pharmaceuticals, reported a transaction on June 13, 2024.
• The transaction involved the vesting of 3,388 restricted stock units, each representing a contingent right to receive one share of Agios Pharmaceuticals' common stock.
• Following the vesting, Smith disposed of 3,388 shares of common stock.
• After the reported transactions, Smith beneficially owns 5,690 shares of Agios Pharmaceuticals' common stock.

Sentiment

Score: 5

Explanation: This is a routine regulatory filing detailing stock transactions by a company director. It doesn't inherently indicate positive or negative sentiment about the company's prospects.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. These filings are closely watched by investors seeking insights into management's perspective on the company's stock.

Comparison to Industry Standards

• Tracking insider transactions is a common practice in the pharmaceutical industry, with companies like Vertex Pharmaceuticals and Gilead Sciences also subject to similar reporting requirements.
• The vesting and subsequent disposal of shares by a director is a typical occurrence as part of executive compensation packages, aligning with industry norms.

Stakeholder Impact

• The transaction has a minor impact on shareholders as it reflects the director's compensation and personal financial decisions.
• The vesting of stock units aligns the director's interests with those of the shareholders.

Key Dates